Press Releases Foresee Pharmaceuticals Co., Ltd.

Equities

6576

TW0006576002

End-of-day quote Taipei Exchange Other stock markets 06:00:00 2024-05-21 pm EDT			5-day change	1st Jan Change
94.2 ^TWD	-0.42%		+0.64%	-2.08%

May. 03	Foresee Pharmaceuticals Co., Ltd. announced that it expects to receive $7.841 million in funding	CI
Apr. 30	Foresee Pharmaceuticals Announces First Subject Dosed in Its First-In-Human Clinical Trial of FP-020	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Foresee Pharmaceuticals Receives Positive Recommendation from DSMB to Continue the Casppian Study, a Phase 3 Clinical Trial of Leuprolide Injectable Emulsion for the Treatment of CPP	Apr. 02	AQ
Foresee Pharmaceuticals to Present at the American Heart Association Annual Meeting Focusing on its ALDH2 activator FP-045 in Pulmonary Hypertension Associated with Interstitial Lung Disease	23-10-31	AQ
Foresee Pharmaceuticals Announces Publication of Preclinical Data in Nature Communications	23-10-02	AQ
Foresee Pharmaceuticals to Present Phase 1/2 Fanconi Anemia Clinical Study Design for its ALDH2 activator FP-045 at the Fanconi Anemia Research Fund 2023 Scientific Symposium	23-10-02	AQ
Foresee Pharmaceuticals Announces Completion of US$42.3 Million Financing	23-06-28	AQ
Foresee Pharmaceuticals Presented Poster on MMP-12 inhibitor, FP-020, in Genetic Model of Sarcoidosis at the WASOG 2023 International Conference on Sarcoidosis and Interstitial Lung Diseases	23-06-22	AQ
Foresee Pharmaceuticals : will attend the investor conference held by Cathay Securities Corporation	22-08-15	PU
Foresee Pharmaceuticals : The submission of an IND for FP-045 in patients with Fanconi anemia by TRPharm to the Ministry of Health of Turkey	22-08-10	PU
Foresee Pharmaceuticals : Typo Corrections to the Company’s 2021 Annual Report	22-08-08	PU
Foresee Pharmaceuticals : Change of Internal Audit Officer of Foresee	22-08-08	PU
Foresee Pharmaceuticals : Board of Directors resolved to approve the 2022Q2 consolidated financial report	22-08-08	PU
Foresee Pharmaceuticals : announces phase 2 results of FP-025 in patients with Covid-19 associated ARDS	22-08-02	PU
Foresee Pharmaceuticals : The Submission of CAMCEVI 42 mg Marketing Authorization Application by Accord Healthcare, Foresee's Licensing Partner, to the MHRA of the UK	22-07-26	PU
Foresee Pharmaceuticals : announces the submission of a phase 3 IND to US FDA for FP-001 42 mg in patients with central precocious puberty	22-07-20	PU
Foresee Pharmaceuticals : will attend the investor conference held by Cathay Securities Corporation	22-07-08	PU
Foresee Pharmaceuticals : 2022 Annual Shareholders' Meeting resolutions	22-06-29	PU
Foresee Pharmaceuticals : announces the submission of New Drug Application for CAMCEVI 42 mg to TFDA	22-06-09	PU
Foresee Pharmaceuticals : announces EMA approval of CAMCEVI 42 mg for the treatment of advanced prostate cancer	22-05-30	PU
Foresee Pharmaceuticals : will attend the 11th Taiwan CEO Week held by Taiwan Stock Exchange and QIC	22-04-18	PU
Foresee Pharmaceuticals : The submission of Marketing Authorization Application by Megapharm for CAMCEVI 42 mg to the Ministry of Health of Israel	22-04-05	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Foresee Pharmaceuticals Co., Ltd.

Equities

6576

TW0006576002

Press Releases

Filters